Williams Cancer Institute +1 (863) 451-9755
Pancreatic Cancer

Pancreatic cancer, treated through a needle where it sits.

The treatment breaks the tumor open with electrical pulses, exposing what your immune system needs to see, then delivers immunotherapy right there — for people told surgery is not an option or that treatment has stopped working.

Start Your Admissions Process How It Works

Complete a short, three-step form to begin your admissions process. One of our patient consultants will contact you to explain the process and guide you through the next steps.

What we do
AblationVaxTreat the tumor. Teach the immune system. Treat locally, act globally.Everything we do is built on AblationVax, the approach Dr. Williams developed: the tumor is treated through a needle (ablation), and the treated tumor becomes an in-situ vaccine: a vaccine made inside your body, from your own cancer.

Treating the tumor itself, where surgery and heat cannot go

Under CT guidance, a WCI physician places a thin needle into the tumor and breaks its cells open with pulsed electric fields, releasing the tumor's own antigens: the markers the immune system uses to recognize cancer. In the same session, immune drugs go into that exact spot. The target can be the tumor in the pancreas or one where the cancer has spread, such as the liver. It works alongside your chemotherapy, not in place of it.

The immune drugs placed in the tumor teach the immune system to recognize this cancer, the way a vaccine does. You teach the immune system in one spot, and it goes after the same cancer in the rest of the body.

1Break it openPulsed electric fields break the tumor's cells open and release its antigens.
2Treat it in placeImmune drugs go into that exact spot, in the same session.
3Teach the whole bodyThe immune system learns the cancer at one tumor and goes after it everywhere else. Doctors call this the abscopal effect. It does not stop there: the cycle below keeps it going.
Video (1:22): Why do electricity and immunotherapy work so well together? Dr. Williams explains AblationVax.
After step 3: how AblationVax keeps working

The intratumoral immune conversion cycle

The treated tumor is the source of the vaccine, and it keeps supplying it. It is not one exposure and done. Every round of tumor cells the immune system destroys exposes new antigens, and those restart the cycle, so the response keeps spreading: broader, throughout the body, and with memory. It turns a “cold” tumor, one the immune system ignores, “hot”.

01DisruptAblation breaks the tumor open and exposes its antigens, the markers the immune system uses to recognize the cancer: not a few, all of them.
02Prime and recruitImmune drugs in that same spot call immune cells in and show them the cancer.
03Activate and co-stimulateCo-stimulation is a second go-signal. Those immune cells are switched on against the antigens the ablation just exposed.
04ReleaseThe checkpoint drugs we inject take the brakes off, so the immune system can kill tumor cells.
05DestroyImmune cells destroy tumor cells, and every cell they kill exposes new antigens.
06RepeatThe new antigens restart the cycle: re-priming, amplifying and spreading the response.

Card 06 leads back to card 02. Doctors call the widening response epitope spreading.

Most cancer vaccines: outside-inMade outside the body from a few pre-selected antigens, the same for everyone, then injected. The response is limited by the antigens someone chose.
AblationVax: inside-outMade inside your body, from every antigen in your own tumor. A vaccine made for one person: you. Not a patch: a rebuilding of the immune system from within.

Electricity, not heat, next to the big blood vessels

Ablation means treating a tumor through a needle, where it sits, instead of cutting it out. Most ablation uses heat, which flowing blood carries away and which can damage the vessels it touches. Pulsed electric fields break open tumor cells without heat and leave the framework of nearby vessels and ducts intact, so tumors wrapped around the main arteries and veins beside the pancreas can be treated. In a 50-patient trial of a closely related technique (IRE), people whose cancer had grown around those vessels lived a median of 17 months from diagnosis.

Helping the immune system see a tumor that hides

Pancreatic tumors are usually "cold": the immune system largely fails to notice them. Part of the reason is KRAS, a gene changed in roughly 9 in 10 pancreatic cancers, which WCI's Dr. Nathan Goodyear describes as building a shield that keeps immune cells out. Breaking the tumor open releases its antigens, so the immune system finally has something to see. The drugs we inject into that spot are chosen to wake the immune system up: some release its brakes, others press the accelerator, and for pancreatic cancer we add drugs aimed at KRAS.

Reaching cancer it never touched

Once the immune system has been alerted at one tumor and kept re-primed by the cycle above, it goes after the same cancer elsewhere in the body, and it remembers it. Doctors call this an abscopal effect. In the case below, only the largest liver tumor was treated, and the record describes the untreated tumor in the pancreas as resolved on imaging.

Standard care. Resectable disease: surgery with chemotherapy. Borderline resectable: chemotherapy, then reassessment for surgery. Locally advanced and metastatic disease: systemic chemotherapy aimed at extending life.

Ablation alone. Local treatment of the tumor where it sits. Where the tumor encases the superior mesenteric artery, celiac axis or portal vein — the pattern that makes surgery impossible — heat-based ablation risks losing heat to flowing blood (leaving tumor behind) and injuring the vessel. Non-thermal ablation does not depend on heat, which is why it is used there.

This approach. We combine non-thermal pulsed electric field (PEF) ablation of the tumor, at the pancreatic primary or at a metastasis, with immunotherapy injected into the same site in the same session. It is given under physician review alongside the patient's current care, not instead of it. The rationale: pancreatic tumors are immunologically "cold" — Dr. Nathan Goodyear's description of KRAS-driven disease is that "it blocks antigen presentation. It actually excludes the T cells, and it builds this fibrotic layer… it creates a shield" (Beyond The Standard, Ep. 19). Breaking the tumor open exposes its antigens, and the injected agents are chosen to make the immune system respond to them. In our clinical observations, treating one tumor produces an immune response at untreated sites, with lasting immune memory; in the written case in the records section, a restaging CT before treatment described a 4.3 × 4.0 cm pancreatic mid-body mass, similar in size to the prior exam, with no flow in the splenic artery and vein (likely thrombosis).

The procedure, step by step

  1. Case review and protocol design. CT or MRI on a pancreas protocol, PET/CT, pathology, CA 19-9 with dates, KRAS and other somatic results, germline testing if done, and the chemotherapy history. The intratumoral combination is designed from the tumor's immune and genetic profile.
  2. Guidance and access. CT-guided percutaneous needle placement into the target tumor, which may be the pancreatic primary or a metastasis.
  3. Ablation. PEF ablation: short high-voltage pulses disrupt tumor cell membranes while sparing the collagen scaffold of adjacent vessels and ducts. Sessions are repeated as the treatment plan sets out.
  4. Intratumoral immunotherapy. Through the same access, into the ablation bed. A small dose of contrast can confirm that the injected drugs have spread through the tumor.
  5. Setting and time. About an hour for the procedure under conscious sedation, and about two hours of recovery. Most procedures are outpatient under conscious sedation; general anesthesia or an overnight stay is rarely required.
  6. Follow-up. Imaging at 6–8 weeks; regular labs including immune cytokines, CA 19-9 and other labs as indicated, and, where used, circulating tumor DNA; coordination with the home oncology team for ongoing systemic treatment; repeat procedures as indicated. The number of treatments is decided with the patient's physician.

Agents. The injected immunotherapy is a multi-agent combination. The agents and doses are set per patient by the treating physician.

The immune conversion cycle, in clinical terms. Ablation disrupts the tumor and exposes its full antigen repertoire, not a pre-selected subset. The injected immunotherapy then remodels the tumor microenvironment, priming, recruiting and activating immune cells and releasing the brakes on them. Immune-mediated lysis exposes further antigens, which re-prime the response (epitope spreading), producing a broader, polyclonal, systemic response with memory, converting a cold tumor hot. This is WCI’s stated rationale, in Dr. Goodyear’s framing, borne out in our clinical observations.

Evidence. The ablation half of this approach has prospective human data in pancreatic cancer, from irreversible electroporation (IRE), the most studied form of pulsed electric field ablation in cancer. In PANFIRE-2, a multicenter, single-arm phase II trial of CT-guided IRE in 50 patients (40 with locally advanced disease, 10 with recurrence after surgery), median overall survival was 17 months from diagnosis of locally advanced disease and 16 months from diagnosis of recurrence [1]. Complications occurred in 29 of the 50 patients (58%; 21 major), one death within 90 days was likely related to the procedure, and the cancer came back at the treated site in 23 (46%) [1]. In an exploratory study of ten patients from the same group's earlier PANFIRE trial, blood tests after IRE showed a temporary fall in regulatory T cells, a temporary rise in activated T cells, and new or boosted T-cell responses against the pancreatic-cancer antigen WT1 in four; the authors concluded that the findings support combining percutaneous ablation with immune therapy [2]. Neither study tested ablation together with immunotherapy injected into the tumor; that combination, in the same session, is what we add. Our own pancreatic record is the written case in the records section below. Sources

  1. Ruarus AH, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology 2020;294(1):212–220. PMID 31687922. DOI 10.1148/radiol.2019191109.
  2. Scheffer HJ, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology 2019;8(11):1652532. PMID 31646081. DOI 10.1080/2162402X.2019.1652532.
What the records show

Two written cases, with the scans

Two patients' courses from our records, with their scans and blood tests exactly as recorded. Not every patient will have the same result.

Case1Complete response

Pulsed Electric Field Ablation with Intratumoral Immunotherapy for BRCA-Positive Pancreatic Adenocarcinoma with Liver Metastases

Pancreatic adenocarcinoma with liver metastases (BRCA+)

In plain words

Chemotherapy had stopped shrinking it. Three short sessions followed.

A man with stage IV pancreatic cancer and many liver tumors, on chemotherapy that was no longer shrinking them. Over four weeks he had three sessions of pulsed electric field ablation with immunotherapy injected into the largest liver tumor. From month 9 the PET scans in the record show no active cancer, and the untreated tumors also resolved on imaging. His tumor DNA in the blood has been undetectable on the test used, on every draw since month 3.

PET/CT scan at Month 9, axial view through the liver
July 2023 · Month 9 · PET/CTCase study Figure 2
Case study

Chemotherapy had stopped shrinking it. Three short sessions followed.

A man who came in with pain under the right ribs and was found to have stage IV pancreatic cancer: a mass in the body of the pancreas (5.3 × 3.7 cm), many tumors in both lobes of the liver (the largest 8 × 7.1 cm), and enlarged lymph nodes near the liver and behind the esophagus. A liver biopsy showed poorly differentiated adenocarcinoma; the CA 19-9 blood marker was 2,764. He carries a BRCA gene change. He was treated with FOLFOX chemotherapy; a restaging scan during that course showed the pancreas mass unchanged, the largest liver tumor slightly larger (9.2 × 8.7 cm), and a blocked splenic artery and vein.

The team then began treating the tumor directly. Over four weeks there were three sessions of pulsed electric field ablation (short bursts of electricity through a needle, to break up tumor cells), with immunotherapy injected into the dominant liver tumor at the same sitting, under CT guidance. Each time, a small dose of contrast confirmed the medication had spread through the tumor.

CT scans at six weeks, four months and seven months each showed improvement. A PET/CT at month 9 showed no active FDG uptake. PET/CT at month 21 showed the treated liver tumor still shrinking, still with no active FDG uptake, and PET/CT with CT at month 29 showed no active FDG uptake, further shrinkage of the treated tumor, and resolution of all the other smaller liver tumors. The untreated pancreas tumor and lymph nodes also resolved on imaging (we propose evidence of an abscopal response). Circulating tumor DNA fell from 58.80 MTM/mL about seven weeks before the first treatment (it had already fallen by about half during the last FOLFOX cycles before the first session) to 0.07 at month 2 (about five weeks after the third session) and has read 0.00 on every draw from month 3 to month 28 (16 consecutive undetectable results). The clinic reports ctDNA undetectable on all draws from month 3 through month 43 (31 draws). The treatment summary records a later PET/CT, about three and a half years on, reported by the clinic as still showing no evidence of disease.

One patient's record, assessed retrospectively, with no comparison group. It cannot show this treatment works better than any alternative, and some patients with the same diagnosis do not benefit.

No FDG uptake on PET/CT at Months 9, 21 and 29, described in the WCI case study as a complete metabolic response. The clinic reports a Month 42 (Year 3.5) PET/CT as FDG negative, about three years and five months after the last treatment.

From the WCI case study: “The dominant, treated hepatic metastasis continues to regress two years post-treatment, with complete radiologic responses to the untreated primary pancreatic tumor, metastatic lymph nodes, and additional hepatic metastases. Furthermore, the circulating tumor DNA decreased to undetectable levels post-treatment, and this has remained undetectable at over 42 months follow-up. [Update from the treating physician: ctDNA remains undetectable at 42 months.]”

Circulating tumor DNA · MTM/mL
58.80→0.00

Clinic update: January 2023 – May 2026 · ctDNA undetectable on all draws from Month 3 through Month 43 (31 draws).

Before Treatment3 sessions Follow-up
58.80
27.83
3.68
0.07
0.00January 2023 – May 2026 · Undetectable · Month 3 → 43
May 2022Month −5Diagnosis
August 2022Month −2CT
October 2022Day 0First session
July 2023Month 9No FDG uptake
July 2024Month 21PET/CT
March 2025Month 29PET/CT
April 2026Month 42FDG negative
Treatment session ctDNA blood test Key scan Other imaging Diagnosis & decisions Time axis widened during treatment

Per the treating physician: the session scans (Days 0, 14 and 29) were taken during the procedure without contrast, so the smaller liver lesions are hard to see on them.

PET/CT

A scan that lights up active cancer cells.

No FDG uptake

Nothing lit up on the PET scan; a scan cannot see every cell.

CA 19-9

A blood marker for pancreatic cancer, read as a trend over time.

ctDNA

Tiny pieces of tumor DNA in the blood; "undetectable" means the test found none.

Complete metabolic response

No active cancer visible on PET.

Hepatic

Of the liver.

Adenocarcinoma

The most common type of pancreatic cancer.

BRCA

A DNA-repair gene; changes in it affect how some cancers respond to treatment.

FOLFOX

A chemotherapy made of three drugs.

Abscopal effect

An immune response at tumors that were not treated.

{{ ph.title }}

{{ ph.span }}
  1. {{ ev.t }} Milestone
    {{ ev.sub }}
    {{ ev.metric }}MTM/mL

    {{ ev.v }}
{{ ph.scansLabel }}
Total delivered {{ ph.note }}
Case2
Early metabolic response (PET): provisional

CT-Guided Pulsed Electric Field Ablation with Intratumoral Immunotherapy for Pancreatic-Tail Cancer

Pancreatic cancer in the tail of the pancreas, near the splenic hilum.

Early metabolic response (PET): provisional · not a response by RECIST/WHO size criteria

In plain words

Treated six times. Seven weeks later, the scan no longer lit up.

A tumor in the tail of the pancreas, near the spleen. Over about 16 weeks it was treated six times: each session broke the tumor open with electrical pulses through a needle and injected immunotherapy into it. After four sessions the tumor was about a quarter smaller and looked mostly like dead tissue on CT. Seven weeks after the last session, the tumor no longer lit up on the PET scan. It is an early result and still needs following.

FDG PET/CT, Day 161 · after treatment
July 2026 · Day 161 · FDG PET/CTEarly, provisional
Case study

A pancreatic-tail tumor treated six times. Seven weeks after the last session, no uptake on PET: an early result.

The patient

The source says the cancer was in the tail of the pancreas, near the spleen. On the first CT (Month −6) the mass measured 33 × 27 mm. Between them the patient received FOLFIRINOX chemotherapy (five cycles). A PET/CT one month before treatment showed focal FDG uptake in that mass, consistent with active tumor.

What was done

Six CT-guided sessions over about 16 weeks (Days 0, 25, 47, 67, 88 and 109). Each session combined pulsed electric field (PEF) ablation, which sends short electrical pulses through a needle electrode placed in the tumor, with immunotherapy injected into the tumor. The injected drug was mixed with contrast so it would show on CT, and the session scans show the deposit inside the lesion.

What the record shows

  • CT, size. By Day 88 the mass measured 25.5 × 22.6 mm: 23% smaller across its longest diameter and 16% smaller across the other. It had changed from solid to mostly low-density tissue, which the radiologist reads as treatment-related necrosis (dead tumor tissue, as read on CT).
    • By size, that is a 23% decrease in the longest diameter, below the 30% that RECIST 1.1 uses for partial response. The radiologist lists it as stable disease by RECIST 1.1. Strictly, though, a formal RECIST category cannot be assigned: the baseline CT was about six months before treatment (RECIST allows four weeks), and this measurement was taken after four of the six sessions.
    • The radiologist notes that size rules tend to understate response after ablation, because the treated zone shrinks slowly even when no live tumor remains.
    • The radiologist’s other frameworks: WHO (bidimensional, −35%): stable disease; Choi (density-based, validated in GIST, supportive only): partial response pending density measurements. Overall impression: favorable local response.
  • PET, activity. About seven weeks after the sixth session (Day 161), the focal FDG uptake seen before treatment was gone: the treated area matched the background. The radiologist reads this as a complete metabolic response of the treated lesion. It is early (about seven weeks after the last session; PERCIST suggests 8–12 weeks after radiation, the nearest comparison) and provisional, until SUV/SUL values with the liver reference are recorded and the two scans are confirmed comparable (same scanner, uptake time, protocol and blood glucose, and no new lesions on the whole-body study). The two PET images also use different colour scales, so the visual comparison needs SUV confirmation. The radiologist notes that inflammation after ablation more often adds uptake than hides it, so an absence of uptake this early is a favorable sign.
  • No local progression was seen on the images provided (single slices only).
  • Distant disease cannot be judged from this document. Each study is shown as a single slice.

Day 161 FDG PET/CT: no focal FDG uptake above background; complete metabolic response of the treated lesion, early and provisional.

Timeline

Course, measured from the first session

Tumor size · CT
33 × 27 mm→25.5 × 22.6 mm
August 2025 → May 2026 · Month −6 → Day 88 · mostly low-density (necrosis)
Activity · FDG PET
Focal uptake→None
January 2026 → July 2026 · Day −29 → Day 161 · early, provisional
Before Treatment6 sessions Follow-up
August 2025Month −6CT
January 2026Day −29PET
February 2026Day 0First session
May 2026Day 88CT · −23%
May 2026Day 109Session 6
July 2026Day 161PET · no uptake
Treatment session Key scan Baseline imaging Time axis widened during treatment

{{ ph.title }}

{{ ph.span }}
  1. {{ ev.t }} Milestone
    {{ ev.sub }}
    {{ ev.metric }}MTM/mL

    {{ ev.v }}
{{ ph.scansLabel }}
Total delivered {{ ph.note }}
Is this for you?

Where this fits, stage by stage

Pancreatic cancer is grouped by whether a surgeon can remove it. Find the card closest to what you have been told. If you are unsure, send your records: a physician decides case by case, from your actual scans.

Resectable, surgery planned

A surgeon can remove it, and surgery with chemotherapy comes first. Where it fits, we can inject immune drugs into the tumor before surgery, to prime the immune system against the cancer before it is removed. This is planned with your surgical team.

Borderline resectable

Chemotherapy comes first, to try to shrink the tumor enough for surgery. During that window we can treat the tumor directly, so the immune system is engaged while the chemotherapy works. Whether this fits is read from your scans.

Locally advanced, not operable

It has not spread to distant organs, but it wraps around major blood vessels, so it cannot be removed. This is the situation our approach is built for: the electrical pulses can treat right next to those vessels, and the injected drugs are aimed at cancer elsewhere in the body too.

Metastatic (stage IV)

It has spread to other organs, such as the liver. We treat one tumor directly, in the pancreas or where the cancer has spread, alongside your chemotherapy, aiming to bring back an immune response worn down by repeated treatment. The written case above is a stage IV case.

You may be a candidate if:

Any of these describes you:

  • Your cancer is locally advanced or cannot be removed
  • You have been told surgery is too risky or not possible
  • The tumor wraps around a major blood vessel (your scan report may say "encasement" of the superior mesenteric artery, celiac axis or portal vein)
  • It keeps growing despite chemotherapy, radiation or immunotherapy given into a vein
  • You want to add immune treatment to the plan you are on
  • You are looking for options beyond your home country

It may not be suitable if:

  • Your liver is failing (this is different from having tumors in the liver)
  • You are not well enough to travel
  • You have a severe infection right now
  • You have a bleeding disorder that cannot be corrected

Each case is individually evaluated by the Williams Cancer Institute team.

  • Resectable, surgery planned — Standard care: surgery with chemotherapy, which comes first. Immune priming inside the tumor before surgery is offered where it fits, to prime the immune system before surgery; decided with the surgical team.
  • Borderline resectable — Standard care: chemotherapy to shrink the tumor, then reassessment for surgery. PEF with intratumoral immunotherapy during that window, with the aim of shrinkage while the immune system is engaged.
  • Locally advanced, unresectable — Surgery is not possible when the tumor encases major vessels. PEF treats next to those vessels; the injected immunotherapy is aimed at disease elsewhere too.
  • Metastatic, stage IV — Standard care: systemic chemotherapy aimed at extending life. Direct treatment of a tumor, aiming to re-engage an immune response worn down by repeated chemotherapy, radiation or IV immunotherapy.

Who we treat: locally advanced or unresectable pancreatic cancer · surgery judged too risky or not possible · tumor encasing the superior mesenteric artery, celiac axis or portal vein · progression despite chemotherapy, radiation or systemic immunotherapy · immune activation sought in addition to the current regimen.

Who we do not treat: liver failure (not the same as tumors in the liver) · very poor performance status (unable to travel) · active severe infection · uncorrectable bleeding disorder. Each case is individually evaluated by the Williams Cancer Institute team.

How it works

Your Admissions Process, in Five Steps

After completing our admissions form, one of our Patient Consultants will contact you to explain the process and guide you through the next steps. Our admissions process is free of charge, including the review of your medical information and, if our medical team determines that you are a candidate, a video consultation. Treatments are generally not covered by health insurance, and WCI does not bill insurance companies.

  1. 01Free

    Initial Contact

    One of our Patient Consultants will contact you to explain the admissions process, answer your general questions, and guide you through the next steps.

  2. 02Free

    Medical Records and Imaging

    Your Patient Consultant will guide you on the required medical records and imaging studies, as well as how to submit them so our medical team can evaluate your case.

  3. 03Free

    Tumor Board Review

    Once the necessary information has been received, our medical team will review your case to determine whether you may be a candidate for our treatments. If necessary, the medical team may request additional studies or information before making a decision.

  4. 04Free

    Video Consultation

    If our medical team determines that you are a candidate, we will coordinate a complimentary Zoom consultation with one of our physicians. During this consultation, you will be able to discuss your case, address your medical questions, and learn about the treatment approach indicated for you.

  5. 05Self-pay treatment

    Treatment Plan and Next Steps

    Following your medical consultation, you will receive a personalized treatment plan that includes the corresponding costs. If you decide to proceed, the next steps will be coordinated to schedule your treatment.

    Most treatments take place in Los Cabos, Mexico; in some cases our medical team may schedule a procedure in Mexico City. Rebyota is given only at our Beverly Hills, California location.

For step 05

What to expect

Your physician confirms the details for your case.

Procedure
About an hour. Most people go home the same day.
Anesthesia or a stay
Conscious sedation is the predominant anesthesia used. It is rare that procedures require general anesthesia or an overnight stay. Your physician tells you which.
Number of treatments
Determined during the treatment plan design.
First check-up
6 to 8 weeks after the last treatment: a scan, and blood tests for your cancer type.
Your oncologist
Kept informed throughout.
Risks

Like any procedure on the pancreas, this carries risks, including inflammation of the pancreas (pancreatitis), bleeding, blood clots in nearby vessels, and leaks from the pancreas or bile ducts. Some pancreatic procedures need general anesthesia and a short hospital stay. Your physician goes through the risks for your case before anything is decided.

Records to send: pancreas-protocol CT or MRI · most recent PET/CT · biopsy pathology report · CA 19-9 results, with dates · KRAS and other genetic results · germline testing, e.g. BRCA, if done · a list of chemotherapy cycles and dates. The physician confirms the list per case.

Setting. Most procedures are outpatient; a pancreatic procedure rarely needs general anesthesia, and an overnight hospital stay is sometimes needed (see step 5).

Follow-up. First check-up at 6–8 weeks: a scan, and blood tests for this cancer type; the number of treatments is decided with the patient's physician; the patient's oncologist is kept informed throughout.

Dr. Jason R. Williams
Jason R. Williams, MD, DABRInterventional oncology
Dr. Williams holding the 2019 Vince Lombardi Cancer Foundation Leaders For A Cure award
Leaders For A Cure2019 · Vince Lombardi Cancer Foundation
The physician who decides every case

Dr. Jason R. Williams

MD, DABR · Director of Interventional Oncology and Immunotherapy

Dr. Jason Williams is a board-certified radiologist who has spent his career putting needles into tumors under imaging. His first patent, in 2003, covered ablation combined with immunotherapy injected into the tumor. A physician since 2000, he opened his first ablation center in 2004 and completed his residency in 2007. He also co-founded Syncromune, whose separate investigational drug SV-102 holds FDA Fast Track status. His tumor board reviews every case.

The team

Meet Our Medical Team

Tap a photo to read their background.
{{ teamSel.r }}

{{ teamSel.n }}

{{ para }}
Where treatment happens

Our Treatment Facilities in Los Cabos

Most of our treatments are performed in Los Cabos, Mexico, in a private hospital setting.

  • Imaging on site, including CT, ultrasound, MRI and digital radiology, for image-guided procedures.
  • Private patient rooms. When an overnight stay is necessary, nursing care is available on the inpatient floor.
  • Located approximately 15 minutes from Los Cabos International Airport (SJD).

Other treatment locations. In some cases our medical team may schedule a procedure in Mexico City. Rebyota is given only at our Beverly Hills, California location.

Aerial view of the Los Cabos marina at sunset
Los Cabos
Waiting lounge overlooking the Sea of Cortez
Patient lounge
Private patient room with ocean view
Private room
CT procedure suite
Procedure suite
Digital radiology room
Radiology
Patient accounts

In their own words

Accounts Williams Cancer Institute publishes, shared with each patient's permission. They span different cancers. Individual results vary and are not guaranteed.

Videos

Pancreatic Cancer on video

Selected Pancreatic Cancer videos from the Williams Cancer Institute channel. Patient stories are shared with each patient's permission. Individual results vary.
The full Pancreatic Cancer playlist on the Williams Cancer Institute YouTube channel.
Next step

Start Your Admissions Process

Complete our admissions form to get started. One of our Patient Consultants will contact you to explain the process and guide you through the next steps, including the medical information and imaging studies required for our medical team to evaluate your case.

info@williamscancerinstitute.com

Start Your Admissions Process
Scan image not available in this build{{ zoomCap }}
{{ zoomCapShown }}